Glucagon-like peptide (GLP)-1 modulators, thiazolidinedione insulin sensitizers, and sodium-glucose cotransporter (SGLT)-2 inhibitors are among the most promising antidiabetic agents to treat NAFLD [16]. This evidence concerns the gene GCG and metabolic dysfunction-associated steatotic liver disease.